Switching from Stelara to a biosimilar for Crohn's disease
Part of Digestive system clinical trials.
This study checks if it's acceptable for people with Crohn's disease to switch from the biologic medicine Stelara to a similar, lower-cost version called Uzpruvo. If you have been stable on Stelara for at least 6 months without needing steroids, you may be able to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate to severe Crohn's disease
- You have been using Stelara (pre-filled syringe) every 8 or 12 weeks for at least 6 months without changes
- You have not used corticosteroids for at least 3 months and have stable disease (e.g., low inflammation markers or symptom scores)
- Your doctor has already agreed with you to switch from Stelara to Uzpruvo
- You have internet access to fill out online questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study follows people with Crohn's disease or plaque psoriasis who are switching from the reference Ustekinumab to a biosimilar (Steqeyma®). It aims to see how well the biosimilar works in real-world settings.
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.